Please participate – Survey of Specialty Care
Have a voice in improving the coordination of referrals for specialty care!
How our Advocacy Council is working for you
AC speakers shared updates with attendees at the Annual Meeting in Seattle.
USP 797: Favorable proposed draft
Proposed standards allow for the continued compounding of allergen extract prescription sets for individual patients while including some new requirements.
ACAAI and AAAAI leaders discuss increased costs, proposed cuts, E&M proposal
The College and Academy leadership met with CMS to express serious concerns about the proposed 2019 reductions in Medicare reimbursement.
Allergists go to Washington
Some of allergy's top leaders converged on Washington, DC to advocate for issues important to you and your patients.
Updated Chapter 797 posted for public comment
Allergen extract is restored as a separate section of the proposed chapter.
USP 797 update related to allergen extract
Update on USP 797 and FDA activities related to compounding of patient-specific allergen vials for immunotherapy
USP roundtable update
The latest from the roundtable on the potential impact of proposed changes to USP 797.
USP Chapter 797 and in-office compounding of allergen extract
We've provided comments to USP acknowledging that proposed standards for the in-office compounding of extracts are reasonable and acceptable.
Medicare disaster plan in wake of Hurricane Florence
An advisory was issued from the Centers for Medicare and Medicaid Services.
Advocacy Council of the ACAAI to oppose proposed 2019 Medicare payment reductions for allergy/immunology
CMS has released the proposed Medicare Physician Fee Schedule Rule for 2019, which includes substantial Medicare payment reductions for A/I.
The importance of allergic disease in public health: an iCAALL statement
This joint statement by iCAALL calls attention to the impact and relevance of allergy specialists.
Venom extracts will not be interrupted/reduced
The production of venom extracts should not be interrupted due to ALK’s departure from the U.S. market.
ALK Discontinuing Venom Allergenic Extract Production
ALK will no longer supply venom extracts in the U.S.
Work with the AMA leads to Anthem fully rescinding modifier -25 cuts
Joint advocacy efforts are successful.
What you need to know now about new Medicare cards
The Centers for Medicare & Medicaid Services (CMS) is removing Social Security Numbers (SSN) from Medicare cards to prevent fraud and fight identity theft.…
15 years of allergen immunotherapy vial sterility testing
Can't see the PDF preview? Access it here.
Discussions with USP
Discussions with USPLeaders of the Advocacy Council and the College had a call with USP officials on Wednesday morning. We had requested it because we'd been t…
DASH FAQ
Are YOU ready to join the fight? Support DASH now.
